Search by therapeutic area for drugs approved by the Food and Drug Administration (FDA) for sale in the
United States. Click on an area below to view the complete list of drugs in that category or
review descriptions for our therapeutic
area list to assist you in your search.
FDA Approved Drugs for Cardiology/Vascular Diseases
Drugs Approved in 2013
Kynamro (mipomersen sodium); Genzyme;
For the treatment of homozygous familial hypercholesterolemia, Approved January 2013
Liptruzet (ezetimibe and atorvastatin); Merck;
For the treatment of hyoerlipidemia, Approved May 2013
Nymalize (nimodipine); Arbor Pharmaceuticals;
For the reduction of incidence and severity of ischemic deficits following subarachnoid hemorrhage, Approved May 2013
Drugs Approved in 2012
Eliquis (apixaban); Bristol-Myers Squibb;
For the prevention of stroke and systemic embolism resulting from nonvalvular atrial fibrillation, Approved December 2012
Juxtapid (lomitapide); Aegerion Pharmaceuticals;
For the treatment of homozygous familial hypercholesterolemia, Approved December of 2012
Vascepa (icosapent ethyl); Amarin Pharmaceuticals;
For the treatment of hypertriglyceridemia, Approved July of 2012
Drugs Approved in 2011
Brilinta (ticagrelor); AstraZeneca;
For the reduction of thrombotic events in patients with acute coronary syndrome, Approved July 2011
Edarbi (azilsartan medoxomil); Takeda;
For the treatment of hypertension, Approved February 2011
Edarbyclor (azilsartan medoxomil and chlorthalidone); Takeda;
For the treatment of hypertension, Approved December of 2011
Xarelto (rivaroxaban); Bayer;
For the prophylaxis of deep vein thrombosis during knee or hip replacement surgery, Approved July 2011
Xarelto (rivaroxaban); Janssen Pharmaceuticals;
For the reduction in the risk of stroke and systemic embolism resulting from atrial fibrillation, Approved November 2011
Drugs Approved in 2010
Amturnide (aliskiren + amlodipine + hydrochlorothiazide); Novartis;
For the treatment of uncontrolled hypertension, Approved December 2010
Pradaxa (dabigatran etexilate mesylate); Boehringer Ingelheim;
For the risk reduction of stroke and embolism due to atrial fibrillation, Approved October 2010
Tekamlo (aliskiren + amlodipine); Novartis;
For the treatment of hypertension, Approved August 2010
Tribenzor (olmesartan medoxomil + amlodipine + hydrochlorothiazide); Daiichi Sankyo;
For the treatment of hypertension, Approved July 2010
Drugs Approved in 2009
Adcirca (tadalafil); Eli Lilly;
For the treatment of pulmonary arterial hypertension, Approved May 2009
Atryn (antithrombin recombinant lyophilized powder for reconstitution); GTC BioTherapeutics;
For the prevention of peri-operative and peri-partum thromboembolic events, Approved January 2009
Efient (prasugrel); Eli Lilly;
for the prevention of thrombotic cardiovascular complications in acute coronary syndromes, Approved July 2009
Livalo (pitavastatin); Kowa Company;
For the treatment of primary hyperlipidemia and mixed dyslipidemia, Approved August 2009
Multaq (dronedarone); Sanofi-aventis;
For the treatment of paroxysmal or persistent atrial fibrillation or atrial flutter, Approved July 2009
Tyvaso (treprostinil); United Therapeutics;
For the treatment of pulmonary arterial hypertension, Approved July 2009
Drugs Approved in 2008
Cleviprex (clevidipine); The Medicines Company;
For the treatment of hypertension when oral therapy is not feasible or not desirable, Approved August 2008
Trilipix (fenofibric acid); Abbott Laboratories;
For the treatment of dyslipidemia, hypertriglyceridemia and hyperlipidemia, Approved December 2008
Drugs Approved in 2007
Azor (amlodipine besylate; olmesartan medoxomil); Daiichi Sankyo;
For the treatment of hypertension, Approved September 2007
Fenofibrate; LifeCycle Pharma;
For the treatment of hyperlipidemia, dyslipidemia and hypertriglyceridemia, Approved August 2007
Letairis (ambrisentan); Gilead;
For the treatment of pulmonary arterial hypertension, Approved June 2007
Soliris (eculizumab); Alexion;
For the treatment of paroxysmal nocturnal hemoglobinuria, Approved March 2007
Tekturna (aliskiren); Novartis;
For the treatment of hypertension, Approved March 2007
Drugs Approved in 2006
Ranexa (ranolazine); CV Therapeutics;
For the treatment of chronic angina in patients failing first-line therapy, Approved January 2006
Drugs Approved in 2005
BiDil (isosorbide dinitrate/hydralazine hydrochloride); NitroMed;
For the treatment of heart failure in black patients, Approved June, 2005
Drugs Approved in 2004
Caduet (amlodipine/atorvastatin); Pfizer;
For the treatment of hypertension, chronic stable angina and vasospastic angina, Approved January 2004
Drugs Approved in 2003
Crestor (rosuvastatin calcium); AstraZeneca;
For the treatment of primary hypercholesterolemia (heterozygous
familial and nonfamilial) and mixed dyslipidemia, Approved August 2003
Levitra (vardenafil); Bayer, GlaxoSmithKline;
For the treatment of erectile dysfunction related to sexual activity in men, Approved September 2003
Drugs Approved in 2002
Altocor (lovastatin) Extended-Release Tablets; Andrx;
Oral tablets for the adjuctive treatment of hypercholesterolemia, Approved June 2002
Benicar; Daiichi Sankyo;
Oral tablet for the treatment of hypertension, Approved April 2002
Imagent (perflexane lipid microspheres); Alliance Pharmaceutical;
Ultrasound contrast agent for improved imaging of the heart, Approved June 2002
Inspra (eplerenone tablets); Pharmacia & Upjohn;
Oral tablets for the treatment of high blood pressure., Approved September 2002
Plavix (clopidogrel bisulfate); Sanofi-aventis;
For the treatment of acute coronary syndrome, Approved February 2002
Remodulin (treprostinil); United Therapeutics;
For the treatment of pulmonary arterial hypertension in patients with NYHA Class II-IV symptoms, Approved May 2002
Drugs Approved in 2001
Advicor (extended-release niacin/lovastatin); Kos Pharmaceuticals;
For the treatment of cholesterol disorders, Approved December 2001
Diovan (valsartan); Novartis;
Oral capsules and tablets for the treatment of hypertension, Approved January 1997 (capsules); July 2001 (tablets)
Natrecor (nesiritide); Scios;
For the treatment of patients with acutely decompensated congestive heart failure, Approved August 2001
Teveten (eprosartan mesylate plus hydrochlorothiazide); Unimed Pharmaceuticals;
Tablets for the treatment of hypertension, Approved November 2001
Tricor (fenofibrate); Abbott Laboratories;
For the treatment of primary hypercholesterolemia, mixed lipidemia and hypertriglyceridemia, Approved September 2001
Drugs Approved in 2000
Angiomax (bivalirudin); The Medicines Company;
For patients with unstable angina undergoing percutaneous transluminal coronary angioplasty (PTCA), Approved December 2000
Argatroban Injection; Texas Biotechnology Corporation, SmithKline Beecham;
Anticoagulant for prophylaxis or treatment of thrombosis in patients with heparin-induced thrombocytopenia., Approved June 2000
Atacand (candesartan cilexetil); AstraZeneca;
For the treatment of hypertension, Approved September 2000
Betapace AF Tablet; Berlex Laboratories;
For treatment of the irregular heartbeats in patients with atrial fibrillation, Approved February 2000
Diltiazem HCL, Extended-Release Capsules; Biovail Laboratories;
For the reduction of high blood pressure, Approved January 2000
Innohep (tinzaparin sodium) injectable; DuPont Merck Pharmaceutical Company;
For the treatment of acute symptomatic deep vein thrombosis, Approved July 2000
Lescol XL (fluvastatin sodium) tablet, extended release; Novartis;
For the use as an adjunct to diet to reduce elevated total cholesterol, Approved October 2000
Micardis HCT (telmisartan and hydrochlorothiazide); Boehringer Ingelheim;
For the treatment of hypertension, Approved November 2000
Nitrostat (nitroglycerin) Tablets; Parke-Davis;
For the acute relief of an attack or acute prophylaxis of angina pectoris due to coronary artery disease., Approved May 2000
Drugs Approved in 1999
Lescol (fluvastatin sodium) capsules, Rx; Novartis;
Treatment for the reduction of triglycerides, Approved June 1999
Mevacor (lovastatin) tablets; Merck;
Treatment for primary prevention of coronary heart disease, Approved March 1999
Niaspan; Kos Pharmaceuticals;
Niacin extended-release tablets, October 28, 1999
Drugs Approved in 1998
Agrylin (anagrelide HCL); Roberts Pharmaceutical;
Treatment for Thrombocythemia, Approved December 1998
CellCept; Roche;
Treatment for the prevention of organ rejection inpatients undergoing heart transplants, Approved February 1998
Diovan HCT (valsartan); Novartis;
Treatment for hypertension, Approved March 1998
Integrilin; COR Therapeutics, Key Pharmaceuticals;
Injection of eptifibatide, Approved May 1998
Micardis (telmisartan); Boehringer Ingelheim;
Treatment for Hypertension, Approved November 1998
Rythmol; Knoll Pharmaceutical;
Treatment for paroxysmal atrial fibrillation, Approved January 1998
Tiazac (diltiazem hydrochloride); Forest Laboratories;
Treatment for chronic stable angina, Approved February 1998
Tricor (fenofibrate); Abbott Laboratories;
Treatment for very high triglyceride levels, Approved February 1998
Viagra; Pfizer;
Treatment for impotence, Approved March 1998
Drugs Approved in 1997
Baycol (cerivastatin sodium); Bayer;
Treatment for high cholesterol, Approved June 1997; withdrawn 8/8/01
Captopril and hydrochlorotiazide; Mylan Laboratories;
Treatment for hypertension, Approved May 1997
Cardizem (R) (Diltiazem HC1 for injection) Monvial (R); Hoechst Marion Roussel;
Delivery system for Monovial, Approved September 1997
Corlopam; Neurex;
Treatment for severe high blood pressure, Approved September 1997
Diovan (valsartan); Ciba Pharmaceuticals;
Treatment for hypertension, Approved January 1997
DynaCirc CR; Novartis;
Treatment for hypertension, Approved February 1997
EDEX; Schwarz Pharma;
Treatment for erectile dysfunction, Approved June 1997
Lescol (fluvastatin sodium); Novartis;
Treatment for coronary atherosclerosis, Approved September 1997
Lexxel (enalapril maleate-felodipine ER); Astra Merck;
Treatment for hypertension, Approved January 1997
Microzide (hydrochlorothiazide); Watson Pharmaceuticals;
Treatment for mild-to moderate hypertension, Approved January 1997
Normiflo; Wyeth;
Treatment for deep venous thrombosis, Approved May 1997
Pentoxifylline; Faulding, Mylan Laboratories;
Generic equivalent of Trental, Approved July 1997
Pindolol; Teva Pharmaceutical;
Generic equivalent of Visken, Approved April 1997
Plavix (clopidogrel bisulfate); Sanofi-aventis, Bristol-Myers Squibb;
Treatment for cardiac atherosclerotic events, Approved November 1997
Posicor; Roche;
Treatment for hypertension and chronic stable angina pectoris, Approved June 1997
ReoPro; Centocor Ortho Biotech;
Treatment for cardiac ischemic complications, Approved November 1997
REPRONEX(menotropins for injection, USP); Ferring Pharmaceuticals;
Generic equivalent of Pergonal, Approved February 1997
Teveten (eprosartan mesylate); SmithKline Beecham;
Treatment for hypertension, Approved December 1997
Verapamil; IVAX;
Generic equivalent of Knoll's Isoptin SR and Searle's Calan SR, Approved December 1997
Warfarin Sodium tablets; Barr Laboratories;
Generic equivalent of Coumadin, Approved March 1997
Zocor; Merck;
Treatment for high cholesterol, Approved November 1997
Drugs Approved in 1996
Covera-HS (verapamil); G.D. Searle, Alza;
Treatment for hypertension and angina, Approved January 1996
Lipitor (atorvastatin calcium); Pfizer;
For the prevention of cardiovascular disease and treatment of hyperlipidemia and dyslipidemia, Approved December 1996
Mavik (trandolapril); Knoll Pharmaceutical;
Treatment for hypertension, Approved May 1996
Muse; Vivus;
Treatment for impotence, Approved October 1996
Pravachol (pravastatin sodium); Bristol-Myers Squibb;
Treatment for cholesterol-lowering, Approved July 1996
Pravachol (pravastatin sodium); Bristol-Myers Squibb;
Treatment for heart disease, Approved April 1996
ProAmatine (midodrine); Roberts Pharmaceutical;
Treatment for hypotension, Approved September 1996
Procanbid (procainamide hydrochloride extended-release tablets); Warner-Lambert;
Treatment for ventricular arrhythmias, Approved January 1996
Retavase (reteplase); Boehringer Mannheim Corporation;
Treatment for patients suffering from heart attack, Approved November 1996
Teczem (enalapril maleate/diltiazem malate); Hoechst Marion Roussel;
Treatment for hypertension, Approved October 1996
Tiazac (diltiazem hydrochloride); Forest Laboratories;
Treatment for hypertension, Approved February 1996
Visipaque (iodixanol); Nycomed;
Diagnostic contrast agent, Approved April 1996
Drugs Approved in 1995
Androderm (Testosterone Transdermal System); TheraTech;
Treatment for primary and secondary hypogonadism, Approved on September 29, 1995
Corvert Injection (ibutilide fumarate injection); Pharmacia & Upjohn;
Treatment for irregular contractions of the heart, Approved December 1995
Prinivil or Zestril (Lisinopril); Merck, Zeneca;
Treatment for hypertension, heart failure, and acute myocardial infarction, Approved November 24, 1995
Toprol-XL (metoprolol succinate); AstraZeneca;
For the treatment of hypertension, angina pectoris and heart failure, Approved January 1995
